

## Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech's website

Lund, September 13 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that data from the recently completed phase I study with the eye drop formulation of laquinimod, a small molecule immunomodulator in development for non-infectious uveitis, together with results from the intraocular biodistribution study of laquinimod eye drops in rabbit, are now available on the company website.

The data were presented in a poster session at the International Ocular Inflammation Society (IOIS) 2023 Meeting in Berlin.

The results presented included safety and tolerability in the phase I randomized, placebo-controlled study with laquinimod eye drops in healthy subjects conducted at the Medical University of Vienna, Department of Clinical Pharmacology. The clinical study (NCT05187403) included 54 healthy subjects who received single doses or multiple doses of laquinimod eye drops in one eye and placebo in the other eye. Laquinimod was demonstrated to be safe and tolerable; no serious adverse events were reported, and ocular assessments did not reveal any tolerability concerns.

In the ocular biodistribution study in rabbit, laquinimod was detected in the cornea and retina /choroid of the rabbit eye following administration of laquinimod eye drops.

A clinical ocular biodistribution study of the eye drop formulation will be conducted at the Byers Eye Institute, Stanford University (Palo Alto, California, USA) with the Principal Investigator Quan Dong Nguyen, MD, MSc, Professor of Ophthalmology, Medicine, and Pediatrics, Stanford University School of Medicine.

Read the poster [here](#).

**For further information, please contact:**

---

Helén Tuveßson, CEO, +46 46 19 21 56, [helen.tuveßson@activebiotech.com](mailto:helen.tuveßson@activebiotech.com)

Hans Kolam, CFO, +46 46 19 20 44, [hans.kolam@activebiotech.com](mailto:hans.kolam@activebiotech.com)

## About Active Biotech

---

**Active Biotech AB (publ) (NASDAQ Stockholm: ACTI)** is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit [www.activebiotech.com](http://www.activebiotech.com) for more information.

## About laquinimod

---

Laquinimod is a first-in-class immunomodulator that promotes immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment. Laquinimod is developed as a new treatment for inflammatory eye disorders in the first step non-infectious uveitis. Laquinimod was previously studied in patients with neurodegenerative and inflammatory diseases, including a phase III randomized study program in multiple sclerosis (MS) patients. The clinical safety and tolerability of laquinimod is well known and preclinical data in disease models support the use of laquinimod for the treatment of severe eye disorders including uveitis and eye disorders with abnormal vascularization.

## Attachments

---

**Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech's website**